sign in sign up
<<
Home , Zonisamide

Vet Times The website for the veterinary profession https://www.vettimes.co.uk

IDIOPATHIC AND SECONDLINE : CATS AND DOGS

Author : Fabio Stabile, Luisa De Risio

Categories : Vets

Date : March 19, 2012

Fabio Stabile, Luisa De Risio conclude their three-part article series (VT42.26 and VT42.28) with a look at other methods for approaching canine and feline treatment

AS discussed by the authors in two previous articles on treating idiopathic (primary) epilepsy in dogs and cats, most epileptic animals are successfully treated with (cats and dogs) or with a combination of phenobarbital and potassium (KBr) (dogs)1,2.

However, 20 per cent to 30 per cent of dogs have poorly controlled epileptic , despite adequate target serum levels of ’first line” anti-epileptic medications, such as phenobarbital and KBr2,3.

In this article we will describe “second-line” anti-epileptic medications, such as , , and zonisamide, which veterinary surgeons can use in combination with phenobarbital and/or KBr in epileptic patients with poorly controlled epileptic seizures.

In addition, some of these “second-line” anti-epileptic medications can be used when phenobarbital or KBr dosage needs to be reduced or discontinued due to intolerable side effects.

Gabapentin

Gabapentin is a structural analogue of gamma-amino-butyric acid (GABA), but does not interact

1 / 10 with GABA receptors, nor does it inhibit GABA uptake, nor is it metabolised into GABA or a GABA agonist.

To date, there has been no consensus on the mechanism of action of gabapentin. Data suggest that gabapentin binds to the ?2? accessory subunit of voltage-gated complexes on the neuronal cellular membrane, and inhibits intracellular calcium influx, with a subsequent reduction in the release of excitatory neurotransmitters (such as glutamate, norepinephrine or -7. substance P) into the synaptic cleft4

Gabapentin has a high oral in dogs (80 per cent administered at a dose of 50mg/kg)8 and its absorption in the small intestine is not influenced by dietary factors9. In dogs, 30 per cent to 40 per cent of the administered oral dose of gabapentin undergoes hepatic metabolism to N-methyl- gabapentin and is excreted by the kidneys8,9.

Despite the reported hepatic metabolism in dogs, there is no evidence of any appreciable induction of hepatic microsomal enzymes8,9.

Peak serum levels are reached two hours after oral administration in dogs10. Gabapentin has a very short elimination half-life in dogs and cats after oral and intravenous administration (three to four hours). Therefore, it needs to be administered (at least) every eight hours6,9.

Because of its short half-life, some authors suggest gabapentin should be administered every six hours to maintain adequate serum concentrations over 24 hours5,11. However, regular administration every six hours is not practical for most pet owners11.

Proposed target serum levels have been evaluated in dogs and reported to range between 4mg/L to 16mg/L12. However, serum gabapentin level monitoring is rarely pursued in the clinical setting due to gabapentin high therapeutic index and the high dose required to cause any sign of toxicity13. The recommended oral dosage of gabapentin is: 10mg/kg to 20mg/kg bodyweight every six to eight hours in dogs4,5,11 and 5mg/kg to 10mg/kg every eight to 12 hours in cats6,11.

The role of gabapentin as adjunctive treatment to phenobarbital and/or KBr for canine idiopathic (primary) epilepsy has been investigated in two clinical studies4,5. The study by Platt et al included 11 epileptic dogs (refractory to phenobarbital and KBr) treated with gabapentin at 10mg/kg every eight hours. The frequency of seizures was estimated from the owners’ diaries during the three months before and after treatment with gabapentin began. Six out of 11 dogs had a reduction in the number of seizures per week equal or greater than 50 per cent – however, there was no significant change in seizure duration. Side effects (ataxia and sedation) occurred in five out of the 11 dogs, but were not severe enough to warrant treatment discontinuation during the study5.

The study by Govendir et al4 included 17 epileptic dogs (considered refractory to phenobarbital and/or KBr) treated with gabapentin at 35mg/kg/d to 50mg/kg/d (divided twice or three times daily)

2 / 10 for four months. There was no significant improvement in overall seizure frequency during the four- month study period. This may be due to the fact gabapentin was administered every 12 hours in the majority of dogs included in this study. Side effects included:

• sedation in three dogs;

• pelvic limb ataxia in six dogs;

• polyuria-polydipsia in one dog; and

• polyphagia in one dog.

However, as polyuriapolydipsia and polyphagia are reported side effects of phenobarbital and/or KBr, it is difficult to establish to which anti-epileptic these side effects may be related to4.

To the author’s knowledge, no clinical studies on the safety and efficacy of chronic gabapentin administration to cats exist.

Pregabalin

Pregabalin is the “next generation” of gabapentin.

Pregabalin has an increased affinity for the ?2? accessory subunit of voltage-gated calcium channel complexes (compared to gabapentin)14,15. Pregabalin is suspected to be a more potent anti-convulsant and antinociceptive agent than gabapentin, on the basis of experimental studies in rodents and clinical trials in humans. More than 90 per cent of pregabalin is excreted unchanged in the urine15. The only study in dogs (administered a single dose of pregabalin orally at 4mg/kg) has shown 80 per cent oral bioavailability, peak concentration at 1.5 hours after oral administration and an elimination half-life of seven hours15. The recommended oral dose of pregabalin in dogs is 3mg/kg to 4mg/kg every eight to 12 hours14.

The role of pregabalin as adjunctive treatment to phenobarbital and/or KBr for canine idiopathic (primary) epilepsy has been investigated in one clinical study that included 11 dogs14. Pregabalin was administered at 3mg/kg to 4mg/kg orally, every eight hours for three months. The number of generalised seizures in the three months before and after initiating pregabalin treatment was recorded.

Seven of the 11 dogs had mean and median seizure reductions of 64 per cent and 58 per cent, respectively. Side effects attributed to pregabalin treatment were reported in 10 dogs and included ataxia and sedation. To minimise side effects, pregabalin can be started at 2mg/kg orally every eight to 12 hours, and be increased by 1.0mg/kg each week until the target dose of 3mg/kg to

3 / 10 4mg/kg is reached14. No information is available on using pregabalin in cats16.

Gabapentin and pregabalin have been reported as effective medications for treating neuropathic -20. pain, chronic pain, cancerous pain or surgical pain in human and veterinary literature17

Levetiracetam

Levetiracetam is a pyrrolidinebased anti-epileptic medication. Its mechanism of action has been postulated to involve inhibition of excitatory neurotransmitter release by binding to the synaptic 23 vesicle protein SV2A21- .

Levetiracetam seems to have a unique ability to suppress seizure activity without affecting normal neuronal excitability21,22. Neuroprotective properties leading to decreased seizures-induced brain damage24, have also been reported25, 26.

Levetiracetam is rapidly absorbed following oral administration and its oral bioavailability has been reported as 100 per cent in recent pharmacokinetics studies performed on healthy dogs and cats27-29. Peak serum concentration is achieved in approximately 40 minutes in dogs and two hours in cats after oral administration28,30,31. Levetiracetam has an elimination half-life of about three to four hours in dogs and three hours in cats – therefore, it needs to be administered (at least) every eight hours21,27,30.

About 70 per cent to 90 per cent of the medication is excreted unchanged in the urine, and it is reported to have no or minimal hepatic metabolism21,27,30. For this reason, it can be used in patients with disease27,30.

Target serum levels (therapeutic range) for levetiracetam have not been definitively established in humans, dogs or cats. Recent pharmacokinetics studies in healthy dogs administered levetiracetam intravenously, intramuscularly, subcutaneously or orally, and in healthy cats receiving levetiracetam orally or intravenously, have suggested that levetiracetam target serum levels may be similar to those proposed to be effective in people (5µg/ml to 45µg/ ml)27,29,31,32. Levetiracetam serum levels are not commonly measured in veterinary patients due to the limited knowledge on target serum levels, the high safety of this medication and the high dose required to cause toxicity16,33.

Toxicity trials on healthy dogs reported no side effects when levetiracetam was administered intravenously as a single dose up to 210mg/kg28.

A one-year toxicological study performed in healthy dogs receiving levetiracetam orally at 1,200mg/kg daily revealed vomiting, salivation and ataxia as the only side effects, with no treatment related mortality11. The recommended dosage of levetiracetam is 20mg/kg every eight

4 / 10 hours in dogs and cats33.

Side effects at the recommended dosage are generally uncommon and include mild sedation and ataxia in dogs and cats, and decreased appetite and transient hypersalivation in cats administered levetiracetam oral solution29,30,33.

Intravenous bolus administration (over two to five minutes) of a single loading dose of levetiracetam at 60mg/kg resulted in the rapid achievement of proposed target serum levels for at least eight hours and no obvious side effects in healthy dogs. Intravenous levetiracetam can be used in treating cluster seizures or status epilepticus. This initial loading intravenous dosage can be followed by the maintenance oral dosage28,34.

A recent clinical research abstract from the American College of Veterinary Internal Medicine (ACVIM) in 2011 investigated the pharmacokinetics of an extended-release formulation of levetiracetam administered orally in five healthy dogs. It revealed a fivefold increment in bioavailability of the extended-release formulation of levetiracetam compared to the immediate- release levetiracetam formulation.

Moreover, levetiracetam plasma concentration eight hours after oral administration were higher than 10µg/ ml, suggesting the extended release formulation may be administered less frequently than the formulation available on the market. No adverse effects were observed in any of the dogs in this study35.

Only one study has evaluated the clinical efficacy of levetiracetam in dogs considered refractory to phenobarbital and/ or KBr33. This study included 22 epileptic dogs (considered refractory to phenobarbital and/or KBr) treated with levetiracetam at 10mg/kg to 20mg/ kg every eight hours for four months. There was significant improvement in overall seizure frequency during the fourmonth study period. After four to eight months of treatment, two-thirds (six of nine dogs) of the dogs that initially responded to levetiracetam treatment suffered an increment in seizure frequency to pre- treatment level. To avoid tolerance to levetiracetam, intermittent short treatment with this medication only during cluster seizures has been suggested as a cost-effective treatment strategy33,36.

In their review on treatment of feline seizures, Bailey et al16 reported treating two cats (suspected idiopathic-primaryepileptic) with levetiracetam monotherapy with successful results. The same authors reported successful results in treating structural epilepsy in two cats with intracranial meningioma, in which seizure activity was not controlled with phenobarbital administration only (Figure 1)16. Unfortunately, studies on the clinical efficacy of levetiracetam in cats are not available.

Zonisamide

Zonisamide is a sulfonamidebased medication. The mechanisms of action include

5 / 10 enhancement of the effect of GABA, modulation of dopaminergic metabolism in the central nervous system, blockage of T-type calcium channels and voltage-gated sodium channels, and inhibition of activity, hence increase of seizures threshold37,38.

Zonisamide is primarily metabolised in the liver by the microsomal enzymes cytocrome P450 and glucuronyltransferase, and it is excreted mainly in the urine and partially in the faeces37,39,40. Its elimination half-life in dogs is about 15 hours with steady-state serum levels occurring three to four days after initiating treatment. Zonisamide elimination half-life is shortened in dogs already treated with phenobarbital due to hepatic enzyme induction of phenobarbital41. For this reason, reported zonisamide dosages for dogs are:

• 10mg/kg orally twice daily when used in combination with phenobarbital; and

-44. • 5mg/kg orally twice daily when used as monotherapy41

The elimination half-life in cats is about 33 hours and, therefore, zonisamide can be administered at 5mg/kg to 10mg/kg every 24 hours, although more pharmacokinetic studies are needed to investigate this further40. The longer elimination half-life in cats compared to dogs is probably due to the feline deficiency of glucuronyltransferase40.

Reported target zonisamide serum levels are between 10 and 40µg/ml in dogs, whereas target range interval has not yet been established in cats 37,45.

In a toxicity study on healthy dogs administered zonisamide at 75mg/kg daily for 52 weeks, the only consistent laboratory abnormalities were a mild decrease in plasma albumin and elevation in liver enzyme activities, and particularly of alkaline phosphatase (ALP)45.

However, no significant differences in liver enzymes level pre and post-zonisamide treatment were noticed in the only two veterinary published studies on the clinical efficacy of zonisamide in idiopathic (primary) epileptic dogs (Figure 2) treated with phenobarbital or a combination of phenobarbital and potassium bromide42,44.

A study investigating the role of zonisamide as adjunctive treatment to phenobarbital and/or KBr for canine idiopathic (primary) epilepsy reported a reduction of seizure frequency in eight out of 11 dogs during the first eight months of treatment44. Long-term follow-up after 17 months revealed a loss of efficacy in three of the eight dogs that had a satisfactory initial response to zonisamide treatment44. The authors suggested possible explanations for this phenomenon were either the induction of tolerance to the medication or increased severity of the epileptic process44. In this study, the authors also reported zonisamide was used as monotherapy in one dog, which achieved 100 per cent reduction of seizure frequency at 17 months follow-up44.

Another study on investigating the role of zonisamide as adjunctive treatment to phenobarbital

6 / 10 and/or KBr for canine idiopathic (primary) epilepsy reported that seven out of 12 dogs had a reduction in seizure frequency of at least 50 per cent, with a median followup of nine months42. Six of these 12 dogs experienced side effects, including:

• ataxia in three dogs treated orally with 6mg/kg to 11mg/kg every 12 hours42;

• transient lethargy in one dog treated with 11mg/kg every 12 hours42; and

• vomiting in one dog treated with 9.5mg/kg every 12 hours42.

Idiosyncratic hepatopathy has recently been described in two dogs (with probable symptomatic or cryptogenic epilepsy) treated with zonisamide monotherapy46,47.

One of the reported dogs developed inappetence and vomiting 10 days after the beginning of the treatment with zonisamide (at 7.7mg/kg orally every 12 hours) and died of acute hepathic necrosis on the 11th day of treatment.

The diagnosis of acute hepatic necrosis was reached based on serum biochemistry results (increased activity of alanine aminotransferase, aspartate transaminase, ALP, gamma-glutamyl transpeptidase and hyperbilirubinaemia), coagulation panel abnormalities (increase in prothrombin time and activated partial thromboplastin time) and postmortem examination46.

The second reported dog, treated with zonisamide monotherapy at 8.3mg/kg orally every 12 hours, developed inappetence, vomiting and icterus 21 days after beginning treatment.

Serum biochemistry abnormalities similar to the above case were noticed, but coagulation panel was unremarkable. The patient survived and achieved complete recovery after adequate supportive care and discontinuation of the zonisamide treatment, along with initiating KBr treatment47.

Renal tubular acidosis has been reported in one dog receiving zonisamide at 7.9mg/ kg to 8.4mg/kg orally every 12 hours, after 18 months of treatment. Serum zonisamide level was 39ìg/ml (target range 10µg/ml to 40µg/ml). The dog was hyperchloraemic, urinary pH was 6.5 and arterial blood gas analysis indicated a primary respiratory alkalosis. Following this report, monitoring of serum electrolytes and acid-base status was recommended in dogs treated with zonisamide48.

There are no publications on the clinical efficacy of zonisamide in epileptic cats. A pharmacokinetics and toxicity study on the use of zonisamide in healthy cats administered 20mg/kg daily for nine weeks revealed that , sedation, , ataxia, vomiting and diarrhoea were the most common side effects40.

In a recent review on diagnosing and treating feline idiopathic epilepsy, Bailey et al16 reported

7 / 10 treating two cats with zonisamide as monotherapy. One of the cats developed severe anorexia and the treatment was, therefore, withdrawn, the other cat experienced a significant reduction in seizure frequency16.

Summary

At present, the use of pregabalin, levetiracetam and zonisamide might be prohibitively expensive for some owners, especially when treating largebreed dogs (Figure 3).

References

1. Berendt M (2004). Epilepsy. In Vite C H (ed). Braund’s Clinical Neurology In Small Animals: Localisation Diagnosis and Treatment, International Veterinary Information Service (www.ivis.org).2. Podell M and Fenner W R (1993). Bromide therapy in refractory canine idiopathic epilepsy, JVIM 7: 318-327. 3. Trapanier L A, Schwark W S and Carrillo J (1998). Therapeutic serum drug concentrations in epileptic dogs treated with alone or in combination with other anticonvulsivants: 122 cases, JAVMA 213: 1,449-1,453. 4. Govendir M and Malik R (2005). Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent, Aus Vet Journal 83(10): 602-608. 5. Platt S R et al (2006). Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy, Vet Record 159: 881-884. 6. Siao K T and Ilkiw J E (2010). Pharmacokinetics of gabapentin in cats, AJVR 71: 817-821. 7. Sills G (2006). The mechanisms of action of gabapentin and pregabalin, Current Opinion In Pharmacology 6: 108-113.8. Radulovic L L et al (1995). Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys, and Disposition 23: 441-448. 9. Vollmer K O and Kolle E U (1986). Pharmacokinetics and metabolism of gabapentin in rat, dog and man, Drug Research 36(1): 830-839. 10. Matar K M (2000). Effect of and gabapentin on pharmacokinetics in the dog, Pharmacol Res 42(6): 517-521. 11. Dewey C (2006). Anticonvulsant therapy in dogs and cats, Vet Clinics North Am Small Anim Pract 36: 1,107-1,127. 12. Bazil C (2002). New antiepileptic drugs, Neurologist 8(2): 71-81. 13. Podell M (1998). Anti-epileptic drug therapy, Clin Tech Small Anim Pract 13: 185-192.14. Dewey C W et al (2009). Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy, JAVMA 235(12): 1,442-1,449. 15. Salazar V et al (2009). Pharmacokinetics of single-dose oral pregabalin administration in normal dogs, Vet Anae Anal 36: 574-580. 16. Bailey K S (2009). The seizuring cat: diagnostic work-up and therapy, J Feline Med and Surg 11: 385-394. 17. Coderre T J et al (2005). Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate, Journal of Neurochemistry 94: 1,131-1,139. 18. Shneker B F (2005). Pregabalin: a new neuromodulator with broad therapeutic indications, The Annual of Pharmacotherapy 39: 2,029-2,037. 19. Cashmore R G et al (2009). Clinical diagnosis and treatment of suspected neuropathic pain in three dogs, Aus Vet Journal 87(1): 45-50. 20. Lamont L (2008). Adjunctinve analgesic therapy in veterinary medicine, Vet Clinics North Am Small Anim Pract 38: 1,187-1,203. 21. Isohaerranen N et al (2001). Pharmacokinetics of levetiracetam and its enantiomer (R)-a-ethyl-2-oxo-pyrrolidine acetamide in

8 / 10 dog, Epilepsia 42(7): 825-830.22. Johannessen S I (2006). Pharmacokinetics variability of newer antiepileptic drugs: when is monitoring needed, Clin Pharmacokinet 45: 1,061-1,075. 23. Lynch B A et al (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam, Proc Natl Acad Sci 101(26): 9,861-9,866. 24. Hanon E (2000). Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischaemia, Seizure 10: 287-293. 25. Loscher W and Rundfeldt C (1998). Antiepileptogenic effect of the novel anticonvulsivant levetiracetam UCB (L059) in the kindling model of , J Pharmacol Exp Ther 284: 474-479. 26. Klitgaar H (2001). Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 42(Supp 4): 13-18. 27. Patterson E E et al (2008). Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics, J Vet Pharmacol Therap 31: 253-258. 28. Dewey C W et al (2008). Pharmacokinetics of single-dose intravenous levetiracetam administration in normal dogs, J Vet Emerg Crit Care 18: 153-157.29. Carnes M B (2011). Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats, AJVR 72(9): 1,247-1,252. 30. Bailey K S (2008). Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy, JAVMA 232: 867-872. 31. Moore S A et al (2010). Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses, Am J Vet Res 71: 337-341. 32. Hardy B T and Cloyd J M (2011). Subcutaneous administration of levetiracetam in healthy dogs, ACVIM Forum Abstract Proceedings: 741. 33. Volk H A et al (2008). The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs, Veterinary Journal 176: 310-319. 34. Cortellini S (2010). Canine status epilepticus care, Veterinary Times 46: 14-18. 35. Platt S R et al (2011). Pharmacokinetic evaluation of extended release levetiracetam in dogs, ACVIM Forum Abstract Proceedings: 729. 36. Loscher W (2006). Experimental and clinical evidence for loss of effect (tollerance) during prolonged treatment with antiepileptic drugs, Epilepsia 47: 1,253-1,284. 37. Matsumoto K et al (1983). Absorption, distubuition and of 3-(sulfamoyl[14C]-methyl)1,2-benziosoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men, Drug Research 33: 961-968. 38. Oommen K J (1999). Zonisamide: a new antiepileptic drug, Clin Neuropharm 22: 192-200.39. Fukunaga K et al (2010). Steadystate pharmacokinetics of zonisamide in plasma, whole blood, and erythrocytes in dogs, J Vet Pharmacol Therap 33: 103-106. 40. Hasegawa D et al (2008). Pharmacokinetics and toxicity of zonisamide in cats, J Feline Med and Surg 10: 418-421. 41. Orito K et al (2008). Pharmacokinetics of zonisamide and drug interaction with phenobarbital in dogs, J Vet Pharmacol Ther 31: 259-264. 42. Dewey C W (2004). Zonisamide therapy for refractory idiopathic epilepsy in dogs, J Am Anim Hosp Assoc 40: 285-291. 43. Thomas W (2010). Idiopathic epilepsy in dogs and cats, Vet Clinics North Am Small Anim Pract 40: 161-179. 44. Von Klopmann T and Tipold A (2007). Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs, JSAP 48: 134-138. 45. Walker R M et al (1988). Chronic toxicity of the anticonvulsivant zonisamide in beagle dogs, Fundamental and Applied Toxicology 11: 333-342. 46. Miller M L et al (2011). Apparent acute idiosyncratic hepatic necrosis associated with zonisamide administration in a dog, JVIM 25: 1,156-1,160. 47. Schwartz M and Olby N J (2011). Possible drug-induced hepatopathy in a dog receiving zonisamide monotherapy for treatment of cryptogenic epilepsy, J Vet Med Sci 73(11): 1,505-1,508. 48. Cook A K et al (2011). Renal tubular acidosis associated with zonisamide therapy in a dog, Vet Intern Med

9 / 10 25: 1,454-1,457.

10 / 10

Powered by TCPDF (www.tcpdf.org)